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Terminal liver disease is a major cause of death globally. The only ultimate therapeutic approach is orthotopic liver
transplant. Because of the innate defects of organ transplantation, stem cell-based therapy has emerged as an
effective alternative, based on the capacity of stem cells for multilineage differentiation and their homing to
injured sites. However, the disease etiology, cell type, timing of cellular graft, therapeutic dose, delivery route,
and choice of endpoints have varied between studies, leading to different, even divergent, results. In-vivo cell
imaging could therefore help us better understand the fate and behaviors of stem cells to optimize cell-based therapy
for liver regeneration. The primary imaging techniques in preclinical or clinical studies have consisted of optical
imaging, magnetic resonance imaging, radionuclide imaging, reporter gene imaging, and Y chromosome-based
fluorescence in-situ hybridization imaging. More attention has been focused on developing new or modified
imaging methods for longitudinal and high-efficiency tracing. Herein, we provide a descriptive overview of imaging
modalities and discuss recent advances in the field of molecular imaging of intrahepatic stem cell grafts.
Keywords: Stem cells, Stem cell therapy, In-vivo imaging, Labeling, Optical imaging, Radionuclides, Super
paramagnetic iron oxide, Reporter genes, Liver regenerationBackground
Liver dysfunction is a serious healthcare problem
worldwide that can progress to fulminant or chronic
liver failure, and eventually deteriorate into end-stage
liver disease. Currently, the only ultimate therapeutic
approach for these diseases is orthotopic liver trans-
plant (OLT). Nevertheless, the potential benefits are
extraordinarily hindered by the major characteristics
of organ scarcity, surgical intervention, postoperative
complication, and life-long immunosuppressive medica-
tion, which have urgently facilitated the exploration of
novel strategies to promote hepatic self-rehabilitation abil-
ity and reverse the pernicious process.
Early observations that stem cells derived from
somatic cells, bone marrow, and embryonic cells ex-
hibit the capacity of multipotential differentiation and* Correspondence: ljli@zju.edu.cn
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might migrate to the injured sites driven by environ-
mental triggers and partly substitute the function of
hepatocytes. Thus, over the last several years, stem
cell-based therapy has emerged as a possible alterna-
tive, revolutionizing the treatment of liver regener-
ation or enabling patients to buy time before liver
transplantation [1–4]. By homing to damaged tissues,
stem cells contribute to alleviating the liver dysfunc-
tion. However, the potential mechanisms involved are
not yet completely understood. Moreover, the disease
etiology, cell type, timing of cellular graft, therapeutic
dose, delivery route, and choice of endpoints have
varied between study groups, leading to different,
even divergent, treatment outcomes. Optimizing stem
cell-based therapies will therefore require a better un-
derstanding of the cellular viability, biodistribution,
differentiation capacity, and long-term fate after en-
graftment, with imaging techniques playing a pivotal
role. Successful implementation of proper cell labeling
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cell therapies.
An ideal imaging technique should most of all be bio-
compatible; that is, with low toxicity to both the labeled
cells and the host. Additionally, the imaging technique
should allow the relatively long-term visualization of in-
fused cells with high temporary and spatial resolution,
and meanwhile be available for histological or functional
analysis. In addition, it is vital that the labeling agent or
marker should be highly specific to original cells, passed
to all progenies, and not transfected to nontarget cells
[5, 6]. To the best of our knowledge, there is no single
imaging method that satisfies all of the ideal conditions.
However, we can combine multiple imaging strategies to
achieve optimal imaging sensitivity, resolution, and time
for follow-up.
Currently, in-vivo cell tracing in liver tissues is per-
formed by direct labeling techniques or reporter gene
labeling. Direct labeling is the most straightforward
method, introducing imaging-detectable probes into
target cells before implantation, including dye-mediated
optical imaging, magnetic resonance imaging (MRI), and
radionuclide imaging. A few researchers have also utilized
Y chromosome-based fluorescence in-situ hybridization
(FISH) imaging. In this review, we discuss the advantages
and disadvantages of these imaging modalities and provide
an overview of the recent advances in the domain of mo-
lecular imaging of intrahepatic stem cell grafts.
Dye-mediated optical imaging
Fluorescent probe labeling was developed for direct-
viewing detection during in-vivo applications of cellular
visualization and monitoring. This method provides the
basis of other subsequently developed tracer techniques.
Connection of fluorophores to labeled stem cells would
allow detection of migrated stem cells by postmortem
liver tissues using a fluorescent microscope. Thus far, a
variety of fluorescent dye has been utilized, which can
reversibly or irreversibly bind to the cell nucleus (e.g.,
4′,6-diamidino-2-phenylindole (DAPI), bis-benzimide
(Hoechst), 5-bromo-2′-deoxyuridine (BrdU)) or the cell
membrane (e.g., PKH26, 1,1-dioctadecyl-3,3,3,3-tetra-
methylindotricarbocyanine iodide (DiR)), or locate in the
nucleus, membrane, and cytoplasm (e.g., carboxyfluores-
cein succinimidyl amino ester (CFSE)).
To date, a large number of animal studies involving
different liver disease models have been promoted as a
result of preclinical data in favor of fluorescent dyes for
stem cell in-vivo tracing (Table 1). For example, the
membrane lipophilic dyes DiR [7] and CM-DiI [8] have
effectively labeled bone marrow-derived mesenchymal
stem cells (BMSCs) and showed no impairment of cyto-
mophology and cell viability. PKH26 is a safe fluorescent
marker with good biocompatibility, although a recentstudy has indicated that PKH26 labeling was not specific
to the transplanted cells [9]. Moreover, the groups of
both Ikeda et al. [10] and Zhan et al. [11] have used
fluorescent PKH26 dye to demonstrate the capacity of
stem cells to differentiate into hepatocytes in pathologic
hepatic environments and express liver-specific markers
Alb, CK8, and CK18.
However, narrow penetration depth and unsatisfactory
photostability of traditional fluorescent dyes are the
most severe limitations for in-vivo imaging even in ro-
dents, let alone use for human intrahepatic detection. In
order to achieve real-time visualization and longitudinal
tracking results, dual or multiple labeling [12, 13] and
new types of near-infrared fluorescence probes (e.g.,
quantum dots (QDs) [14], conjugated polymer-based
water-dispersible nanoparticles (CPNs) [15]) have been
implemented to optimize molecular imaging. QDs consist
of inorganic semiconductor nanoparticles, provide a nar-
row emission spectrum to reduce autogenic fluorescence,
allow exact single molecule positioning, and possess su-
perior photostability. Peripheral intravenous delivery of
QD-labeled MSCs has been successfully tracked in the
liver for at least 2 days [16]. While in cardiovascular appli-
cation, QD-labeled stem cells were reported to maintain
in the heart for at least 8 weeks [17]. The particular optical
advantages make QDs seem to be promising candidates
for long-term in-vivo imaging for liver regeneration.
Proper cell labeling is essential to better understand
cellular biology and provide clues for stem cell therapies.
In most of the cell tracking animal studies, stem cells
were well distributed in the liver after transplantation
for a relatively long-term period through the spleen or
portal vein. This may indicate that peripheral intraven-
ous injection is not the optimal route of cell therapy for
renewal of liver function owing to the major cell reten-
tion outside the liver. In addition, no studies have shown
impaired cell viability and differentiation ability. Thus,
because of their relative safety, high efficiency, low cost,
and ease of use, fluorescent probes have gained extensive
application for both in-vivo and in-vitro experiments.
Fluorescence probes provide high sensitivity and allow
for multiple labeling according to their different optical
spectrum characteristics [18]. They emit varying inten-
sities and colors of fluorescence simultaneously or suc-
cessively to satisfy the different requirements of tracing.
However, poor spatial resolution, shallow penetration,
and inevitable light decay along with cell division have
largely restricted this imaging strategy to visualizing
deep anatomy such as hepatic sinusoid without invasive
manipulation. New types of nanoparticle probes (e.g.,
QDs) have emerged to circumvent some of the prob-
lems, but the high doses may increase nontarget binding
and the safety issue still requires attention [19]. Therefore,
dye-mediated optical techniques are currently suitable for
Table 1 Intrahepatic animal stem cell tracking studies with dye-mediated optical imaging
Study Species (n) Animal model Cell type Agent Delivery/number
of cells infused
Study observations




DiR Caudal vein/106 At 5 days after transplantation, a strong
fluorescent signal from labeled CXCR4
MSCs was almost distributed in the liver,
whereas in the null group the liver and
spleen transmitted nearly the same
signal intensity







Detection of fluorescence-labeled cells
after 1 week
The labeling procedure did not impair
cytomophology
The fluorescent images showed that the
IOD was significantly larger in experiment
group, and the signals presented unevenly
distribution in the fibrous liver tissue
Ikeda et al., 2008 [10]/







PKH26 Portal vein/107 The red fluorescent cells demonstrated
the capacity of stem cells to migrate,
proliferate, and differentiate in pathologic
hepatic environments after engraftment






Caudal vein/105 Luminescent binucleated cells were
seldom observed both in vitro and in
vivo for a long-term follow-up period
After 4 days, most BMSCs grafted to the
tumor focus, and after 20 days, labeled
MSCs almost accumulated in the tumor
stroma






DiR-labeled cells accumulated in the
spleen within 30 min, moved to the liver
at 3 hours, disseminated to almost all
regions of the liver at 24 hours, and
faded at 72 hours
GFP-positive cells were found under
the liver capsule and were still detected
after 2 weeks




CPN Caudal vein/106 Postmortem liver tissue showed the
presence of luminescent cells at the
injury lesions and retained there
The labeling process did not impair the
marker expression, multilineage
differentiation ability, or cell viability




QDs Caudal vein/106 Within 10 min, 70 % of fluorescent signal
retained in the lungs and 30 % of signals
came from the liver when AD-MSCs were
transplanted with heparin
After 1 day, the accumulation rate
decreased to 10 % in both organs and
maintained for at least 2 days
CCl4 carbon tetrachloride, BMSC bone marrow-derived mesenchymal stem cell, ALF acute liver failure; CXCR4 chemokine CXC receptor 4, CBDL common bile duct
ligation, IOD integral optical density, HSC hematopoietic stem cell, TGPC tooth germ progenitor cell, HCC hepatocellular carcinoma, GFP green fluorescent protein,
RFP red fluorescent protein, APAP acetaminophen, ESC embryonic stem cell, PHx partial hepatectomy, CPN conjugated polymer-based water-dispersible nanoparti-
cles, AD-MSC adipose-derived mesenchymal cell, QD quantum dot, DAPI 4′,6-diamidino-2-phenylindole, BrdU 5-bromo-2′-deoxyuridine, DiR
1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide
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have to face great challenges before they can be pushed
into clinical practice.
Magnetic resonance imaging
With the development of molecular imaging, MRI has
emerged as a noninvasive and sensitive technique for
longitudinal tracing of the distribution, retention,homing, and differentiation of transplanted progenitor
cells in intact living organisms. Since MRI combines
high spatial (25–100 μm) and soft-tissue resolution with
free selection of the imaging plane [18], MRI techniques
have been widely applied in animal research for in-vivo
tracing of transplanted stem cells (Table 2).
Currently, gadolinium chelates (Gd3+-DTPA) and
superparamagnetic iron oxides (SPIO) are the most
Table 2 Intrahepatic animal stem cell tracking studies with MRI
Study Species (n) Animal model Cell type Agent Delivery/number of
cells infused
Study observations






Mesenteric vein/106 Detection of modified cells for up to 2
weeks post transplantation
Labeled cells were still present in the liver
intralobular parenchyma after 2 weeks
The labeling process displayed good
biocompatibility




SPIO Splenic vein/107 Hypointense MRI images were detected
until 7 days
The attenuation of MRI signals mainly
arose from excretion of SPIO
Fluorescence and PB staining showed
that the SPIO particles were still inside
the stem cells
The location of AD-MSC accumulation was
well integrated with the liver injury focus






An oval hypointense area at injection
sites was visible within 2 weeks by MRI,
while the signal intensity decreased
with time
PB stain showed the presence of
Feridex-labeled cells in the liver sinusoid




SPIO Caudal vein/106 Detection of grafted cells after 8 days
PB stain revealed SPION containing stem
cells accumulated in the liver parenchyma,
particularly along sinusoids and portal areas




SPIO Portal vein/106 Detection of cells up to 12 days
Signal intensity loss of MRI appeared a
granular pattern
Matching areas stained positive for PB and
CD90 antigen of postmortem liver tissue
showed the SPIO particles were retained
in the originally labeled cells




SPIO Hepatic artery/106 Hypointense MRI images faded over time
and were detected within 7 days
Cell viability was not impaired by labeling
procedure for up to 4 weeks
PB staining and DAPI-stained blue
fluorescent nuclei showed the presence of
original iron particles containing cells




SPIO Mesenteric vein/106 Detection of grafted cells for 12 days in
BMSC-labeled group, but for only 3 days
in cell-free SPIO group
PB staining showed the presence of
originally labeled cells in the portal region
at 3 days, and mainly in the injured areas
of intralobular parenchyma at 15 days








Detection of transplanted cells after 14 days
The decrease of MRI signal intensity was
more obvious in MNP-tagged group. Masson
trichrome staining and autofluorescent
images of MNP-tagged cells showed most
stem cells migrated to the fibrous septa




SPIO Splenic vein/106 Detection of injected cells for up to 2 weeks
No visible blue particles were found in
unlabeled cells after PB staining
Grafted cells were mainly distributed in
periportal and injured areas
CCl4 carbon tetrachloride, BMSC bone marrow-derived mesenchymal stem cell, PEG-g-PEI-SPIO superparamagnetic iron oxide nanoparticles coated with polyethyl-
ene glycol-grafted polyethylenimine, AD-MSC adipose-derived mesenchymal cell, SPIO superparamagnetic iron oxides, PB Prussian blue, DAPI 4′,6-diamidino-2-phe-
nylindole, PHx partial hepatectomy; MRI magnetic resonance imaging; EPC endothelial progenitor cell, ALF acute liver failure; DMN dimethylnitrosamine; MNP
fluorescent magnetic nanoparticle
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with MRI. Lanthanide gadolinium, known as T1 contrast
agent, produces an enhanced intensity zone on T1-
weighted MRI images, while SPIO nanoparticles generate
hypointense areas with the T2 modality. Superparamag-
netic agents are usually composed of a crystal core, typic-
ally 3–5 nm in mean diameter. Because of their good
biocompatibility and high relaxivity, SPIO nanoparticles
have been considered to be a preferred MRI agent tracer
for cell labeling. Moreover, these contrast agents have
been FDA approved as a liver agent for clinical use (SPIO:
Feridex, USA; Endorem, Europe) [20].
Much effort has been made to optimize the internal-
ization process for high-efficiency cellular magnetic la-
beling of stem cells, since they lack the ability of
phagocytosis. So far, the most commonly used method is
magnetofection, which requires transfection agents
(most are cationics), such as lipofectamine, poly-L-lysine,
dextran, and protamine sulfate, to envelop SPIO nano-
particles by electrostatic interactions and pass through
the cell membrane [21]. Nonionic dendrimer-coated
SPIO particles have also been reported to track BMSCs
in rats with liver fibrosis for 2 weeks [22]. One disadvan-
tage of current commercially available transfection
agents is the long incubation periods resulting in the risk
of altering their properties, although no research has
shown that the transduction procedures influenced the
viability or multilineage differentiation potential of stem
cells in appropriate media and activated inflammatory
response [23]. To achieve high uptake rates and efficient
labeling, SPIO were reported to have been derivatized
with HIV-Tat protein-derived peptide sequences for
in-vivo tracing [24]. In numerous preclinical studies,
various stem cell lines have been effectively labeled by
magnetofection and tracked in the liver for several
weeks using MRI in vivo [25–29]. The hypointense
MRI was well integrated with the focus of liver injury,
indicating that transplanted stem cells have the ability
to home to where they are most needed. However, these
agents are not yet clinically approved, which may raise
safety concerns with patients for their potential toxicity.
Another strategy to induce intracytoplasmatic magnetic
labeling is magnetoelectroporation (MEP), a more rapid
and efficient method to mediate endocytosis of SPIO [30].
Based on the mechanism of lower voltage pulses, this
technology does not require transfection agents, which to
some extent circumvents a major barrier for clinical appli-
cation. Although there have been no animal or clinical
studies using magnetoelectroporation for labeling of intra-
hepatic stem cell grafts, further explorations can be
prompted. In addition, fluorescent magnetic nanoparticle
(MNP), a new commercially tagging material, was applied
in a liver cirrhosis rat model [31]. MNP obtains the strong
points of both magnetism and optics, and no transfectionagents are needed for cell labeling, thus also efficiently
avoiding potential threats for the clinic.
The mechanisms of gradual signal intensity restoration
of MRI are not yet fully understood. Several scholars
have attributed the signal drop mainly to the excretion
of SPIO, which was confirmed by histological examin-
ation in the study by Zhao et al. [23], by coincidence
capturing the possible excretion route of SPIO and
showing that the liver macrophages engulfed cell frag-
ments together with the SPIO agent. Another group
showed no Kupffer cells containing blue particles were
observable on histological analysis [32]. Thus, the pro-
posed mechanism was that the labeled cells were grad-
ually mobilized out of the liver. Consequently, a major
limitation of MRI is that the direct-viewing detection of
labeled cells depends on the appearance of SPIO within
the cells. It is difficult for us to recognize the iron parti-
cles released from labeled cells. False positive results
might occur if neighboring hepatocytes engulf the iron
oxide [33]. Another disadvantage is that SPIO, as a T2
contrast agent, produces gradually attenuated intensity
areas on MRI images during the follow-up period, thus
rendering it difficult for quantification, because it is diffi-
cult to draw cause–effect conclusions about the signal
intensity and cell viability [14]. Finally, regarding clinical
application, people with implant cardiac pacemakers or
metal foreign bodies are contraindicated.
Despite these concerns, MRI has potential for short-
term or long-term tracing of intrahepatic dynamic mi-
gration processes of stem cells. MRI can provide
three-dimensional imaging with high spatial and tempor-
ary resolution, which is well suited for implementing the
subtle positioning, such as in the sinusoids, portal, or peri-
hepatic areas, and performing qualitative analysis of stem
cell fate and behavior. Several scholars have demonstrated
the feasibility of MRI for noninvasive visualization of vari-
ous stem cells grafted to cardiovascular tissue and the ner-
vous system for clinical trials [34–36]. In the field of liver
diseases, the move of regeneration medicine from bench
to bedside remains to be undertaken. Novel developments
in MRI-visible tagging materials need to be focused on to
further achieve this transition.
Radionuclide imaging
Single-photon emission computed tomography (SPECT)
and positron emission tomography (PET) are highly sen-
sitive (10–11–10–12 mol/l) modalities available for radio-
nuclide imaging, which can separately detect γ-emitting
isotopes (e.g., 111In, 131I, 99mTc) and positron-emitting
isotopes (e.g., 18F, 124I, 68Ga) with short half-lives to fol-
low cellular trafficking and biodistribution [18]. PET has
a preferable spatial and temporal resolution (~1 cm/sec-
ond to minute) to SPECT (1–2 cm/minute), but is far
inferior to MRI [37]. Like optical labeling methods, stem
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tracers, which passively penetrate the cell membrane
and bind to different intracellular components within a
short time [38].
In-vivo radionuclide imaging of infused stem cells la-
beled with various isotopes has shown promising results
for noninvasive tracing in both preclinical and human
studies, although the labeling technique has not been
widely used for intrahepatic applications. For clinical trials
in humans, 111In-oxine, 99mTc, and 18F-FDG are the most
extensively used agents for PET or SPECT imaging.
Gholamrezanezhad et al. [39] recruited four patients
with uncompensated liver cirrhosis into a study, and
the patients underwent intravenous injection of 111In-
oxine-labeled MSCs with tagging efficiency from 36
to 53 %. SPECT images showed constantly increasing
radioactivity in the liver within 10 days post infusion
and no unexpected side effects occurred over 1 month
of follow-up. In another clinical phase 1 study, the
migration of 99mTc-labeled bone marrow-derived
mononuclear cells following hepatic arterial transplant
into eight patients with liver cirrhosis was identified
by scintigraphy [40]. In-vivo imaging after 3 and
24 hours showed 41 % and 32 % of the total radio-
activity, respectively, in the liver tissue. Ameliorative
liver function by biochemical tests was also observed.
However, some persistent disadvantages cannot be
ignored. The short half-lives of radioisotopes, such as
99mTc with 6 hours, 18F with 110 minutes, and 124I with
4 hours, largely limit the long-term detection of radio-
activity, so that only the immediate imaging of cellular
behavior can be analyzed. For example, the group of Li
et al. [41] provided evidence for the mobilization of 131I-
labeled induced pluripotent stem cells (iPSCs) after per-
ipheral infusion from their original localization to the
liver of mice. Serial monitoring of radioactivity signals
by γ-camera revealed that the in-vivo signal intensity
suffered a progressive recession at 12 hours post cell
transplantation. Additionally, time-dependent cytotoxic
effects and ionizing radiation damage to target cells still
need to be properly assessed. Because radiotracers may
risk being excreted from the originally labeled cells,
confusing signals could be generated from free radio-
active isotopes, which can lead to inaccurate investi-
gations [42].
In summary, the successful implementation of tra-
cing isotope-labeled stem cells homing to the liver
demonstrates the feasibility of radionuclide imaging as
a noninvasive tool to monitor cell delivery, biodistri-
bution, and fate for clinical practice. However, the
short half-life of radionuclides is the major clinical
barrier for long-term tracing. Longer-lived radioiso-
topes should be explored in the future, also taking
into account the biosecurity and practicability.Reporter gene labeling
Direct labeling modalities universally suffer from inevit-
able signal attenuation, accompanied by cellular division
over time. To circumvent this limitation, reporter
gene imaging was developed to trace the multilineage
of progenitor cells in complex systems of interest.
The reporter genes are transferred into the genome
of target stem cells via viral or nonviral methods, in-
cluding transfection of expressing plasmid cDNA,
transduction with lentiviral/adenoviral/cytomegaloviral
vectors, or acquisition from transgenic animals [43].
Once they are incorporated, the reporter genes, which
are activated by endogenous or exogenous promoters,
encode the overexpression of various reporter proteins,
such as fluorophores (green fluorescent protein (GFP)),
enzymes (herpes simplex virus type 1 thymidine kinase
(HSV-tk), luciferase, β-galactosidase), receptors (dopamine
2 receptor), and transporter proteins (sodium iodide sym-
porter (NIS)) [37]. After the implementation of reporter
probes, the generated signals are immediately captured by
different imaging devices; for example, optical charge-
coupled device (CCD), SPECT, or PET.
Intrahepatic cell tracking using reporter genes has
shown a promising outlook, although the technique is
currently used in animal studies for some ethical con-
cerns (Table 3). Real-time visualization of the cellular
biodistribution in the liver was dynamically assessed by
luciferase-based bioluminescence imaging (BLI) [44–46].
Bioluminescence provides excellent sensitivity reaching
10–15–10–17 mol/l and relatively high throughput, but it
is limited by a weak depth of penetration of 1–2 cm with
a high absorption rate in hemoglobin [47]. Furthermore,
the luminescent cells in damaged liver tissue exhibited a
hepatocyte-like morphology and human alpha fetal pro-
tein (AFP) expression was detected in corresponding re-
gions, which well documented that liver regeneration
was motivated by the homing behavior of stem cells to-
ward environmental cues and their potential hepatogenic
differentiation [48]. Another widely used reporter gene
is GFP for fluorescent imaging (FLI) [49, 50]. Encour-
aging results have been found by Song et al. [51], show-
ing that implanted GFP-positive cells could survive in
the liver for up to 18 weeks and accounted for approxi-
mately 40–50 % of regenerative hepatocytes. However,
the limitation of relatively low spatial resolution is simi-
lar to that of dye-mediated optical imaging. NIS is a
transmembrane glycoprotein mainly expressed in the
thyroid glands and mediates the process of iodine intake.
Reporter genes for nuclear imaging based on NIS (PET
or SPECT) are also available with the advantage of quan-
titative analysis and potential clinical prospects [52, 53].
Other types of available reporter genes include galactosi-
dase genes (LacZ) for bioluminescence imaging [54] and
HSV-tk for PET [55].
Table 3 Intrahepatic animal stem cell tracking studies with reporter genes









Mice (12) NOD-SCID model Xenogeneic
EPCs
Luc BLI Directly intrahepatic
into parenchyma/105
Detection of luminescent stem
cells for at least 1 week
Boeykens et al.,
2013 [46]





Luc BLI Portal vein and tail
vein/106
Detection of luminescent stem
cells for 24 hours
Intraportal cell injection was
superior to intravenous cell
injection for homing capacity









visible for 2 months
Labeled cells exhibited a
hepatocyte-like morphology
and AFP expression was









EGFP FLI Tail vein/106 Labeled cells were detected
for up to 6 weeks
The presence of double-positive
cells for EGFP and α-SMA in the
fibrous liver demonstrated the














GFP-positive cells could be
visualized for up to 18 weeks,










Tail vein/105 NIS-MSC mediated concentration
of iodine radioisotopes was
detected in 74 % of tumors with
a half-life period of 4 hours









NIS 131I (γ-camera) Tail vein/105 NIS-MSC mediated concentration
of radioisotopes was detected in
67 % of tumors with a half-life
period of 3.7 hours
Kanazawa et al.,
2011 [54]







Portal vein/106 BLI and histological findings
showed that injected stem cells
survived in the remnant liver for
up to 168 hours
LacZ-positive stem cells were
mainly located around the
periportal regions
NOD-SCID nonobese diabetic–severe combined immunodeficiency disease, EPC endothelial progenitor cell, Luc luciferase, BLI bioluminescence imaging, PHx partial
hepatectomy, MCD methionine/choline-deficient, BMSC bone marrow-derived mesenchymal stem cell, CCl4 carbon tetrachloride, ALF acute liver failure, AD-MSC
adipose-derived mesenchymal cell, Fluc firefly luciferase, AFP alpha fetal protein, EGFP enhanced green fluorescent protein, FLI fluorescence imaging, α-SMA alpha
smooth muscle actin, LPC liver progenitor cell, GFP green fluorescent protein, HCC hepatic cellular cancer, NIS sodium iodide symporter, PET positron emission
tomography, I/R ischemia–reperfusion, LacZ galactosidase genes
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and well tolerated, the signals radiating from reporter
genes cannot be easily diffused or diluted with cell div-
ision, which is appropriate for long-term in-vivo tracing
and monitoring [5]. Since this labeling technique re-
quires molecular manipulations of the stem cells before
transplantation, concerns over theoretical risks and
feasibility for clinical application must be fully assessed,
including: viral vector toxicity from xenogenic materials;the expression stability of reporter genes before migrat-
ing to the liver; precise integration into the injured liver
as much as possible; hepatic immunogenic responses to-
wards accumulation of reporter gene products; and eth-
ical problems [56, 57].
Y-chromosome marker
The Y-chromosome marker has been utilized in a few
sex-matched studies in which cells isolated from male
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us to track the biological actions of transplanted stem
cells via the molecular-cytogenetic FISH technique For
example, a clinical cell imaging study was successfully
performed in four female patients with confirmed alco-
holic hepatitis, who underwent cross-sex stem cell trans-
plantation [58]. FISH for the Y chromosome with
immunostaining demonstrated the differentiation ability
of BMSCs into hepatic myofibroblasts. Using a Y-
chromosome-selective probe, the tracing method avoids
the latent problems of viral vector transduction, trans-
genic labeling, cytotoxic effects, signal decay, or diffusion,
making it fairly suitable for the long-term assessment of
donor cells in recipients [59]. The technique is also easy
to perform with high labeling efficiency, and is barely af-
fected by tissue types and phenotype changes. However,
the fatal weakness is that Y-chromosome marker cannot
apply to autologous transplantation or female donors.
Conclusion and perspectives
To date, quite a few clinical trials of stem cell-based ther-
apies have been performed focusing on liver regenerationFig. 1 Schematic of direct labeling techniques for intrahepatic stem cell tra
the cells through various mechanisms, such as passive transport (fluorescen
(18F-FDG). Fluorescent dyes can respectively bind to the cell nucleus, mem
intracytoplasmatic magnetic labeling using SPIO. Tagged stem cells can be
MRI, PET, or SPECT. TA transfection agent, SPIO superparamagnetic iron oxid
4',6-diamidino-2-phenylindole, BrdU 5-bromo-2'-deoxyuridine, DiR 1,1-diocta
rescein succinimidyl amino ester[60, 61]. However, most cases are in the early phase I/II
stage. Improved liver function has been found to be small
in some studies, and an average of only 55 % patients
showed amelioration in histological tissues [62]. There is
still a long way to go until the widespread application of
stem cell therapies in clinical practice, which prompts us
to translate from bedside to bench to furnish deeper in-
sights into the fate of stem cells and treatment mecha-
nisms. Imaging processes using direct labeling strategies
and reporter genes enable us to elucidate key issues, in-
cluding cellular survival, migration, biodistribution, and
hepatogenic differentiation. The existing imaging strat-
egies differ mainly in terms of depth penetration, spatial
and temporal resolution, sensitivity, quantitative degree,
molecular probes, and cost of imaging modalities.
Every tracing technique has its inherent advantages
and shortcomings owing to different mechanisms of
action (Figs. 1 and 2). MRI is excellent for spatial
resolution and soft-tissue contrast, but is far less sen-
sitive than fluorescent imaging (10–9–10–12 mol/l) or
radionuclide imaging (10–11–10–12 mol/l) [18]. Optical
imaging allows for multilabeling and high-efficiencycing. Stem cells are incubated with different tracer agents that enter
t dyes, 111In-oxine, 99mTc), endocytosis (SIPO), and uptake transporter
brane, or cytoplasm. Magnetofection and MEP are two methods for
detected by imaging equipments, such as fluorescent microscope,
es, 18F-FDG 18F-fluorodeoxyglucose, MEP magnetoelectroporation, DAPI
decyl-3,3,3,3-tetramethylindotricarbocyanine iodide, CFSE carboxyfluo-
Fig. 2 Schematic of reporter gene labeling for intrahepatic stem cell tracing. The reporter genes are transferred into the genome of target stem
cells via transfection, transduction with viral vectors, or acquisition from GM animals. Activated by promoters, reporter genes encode various
reporter proteins, such as fluorophores (e.g., GFP), enzymes (e.g., luciferase), transporter proteins (e.g., NIS), and so forth. Generated signals are
captured by different imaging devices; for example, optical charge-coupled device, SPECT, or PET. GM genetically modified, GFP green fluorescent
protein, NIS sodium iodide symporter
Cen et al. Stem Cell Research & Therapy  (2016) 7:143 Page 9 of 11tracking, but is limited by unstable photobleaching and
weak tissue penetration. The persistent expression of re-
porter genes is fit for long-term tracing. Nevertheless,
concerns about the ionizing radiations from radioisotopes,
leakage or diffusion of tracers, and immunogenic and eth-
ical issues with reporter genes still require attention. A
qualitative outline comparing some general features of
these imaging modalities is presented in Table 4. The idealTable 4 Comparison of characteristics of imaging modalities availab
Imaging technique Probes Imaging methods
Fluorescence imaging Fluorophores, QDs, GFP/RFP Direct labeling/
reporter genes
Bioluminescence imaging Luciferin Reporter genes
MRI SPIO, gadolinium Direct labeling
SPECT 111In, 99mTc, 131I Direct labeling/
reporter genes
PET 18F, 124I Direct labeling/
reporter genes
+ common, ++ good, +++ excellent; $ cheap, $$ expensive, $$$ very expensive
QD quantum dot, GFP green fluorescent protein, RFP red fluorescent protein, MRI m
photon emission computed tomography PET positron emission tomographyimaging method for each study must be determined in
light of the high sensitivity, resolution, and tracing time.
Noninvasive in-vivo imaging of stem cells stands at a
critical point during the transition of treatment from
bench to bedside. Clinical barriers will remain until the
optimal cell types, timing of cellular graft, therapeutic
dose, delivery route, and choices of endpoints are ad-










+++ + ++ + +to++ $
+++ + ++ + +to++ $
+ +++ + +++ ++
++ ++ + +++ ++ $$
++ ++ + +++ +++ $$$
agnetic resonance imaging, SPIO superparamagnetic iron oxides, SPECT single
Cen et al. Stem Cell Research & Therapy  (2016) 7:143 Page 10 of 11scale clinical studies combined with imaging strategies
to explore the trail of cell tracking in patients with
liver diseases in the near future. Novel imaging strat-
egies or combining imaging modalities might help to
shed new light on the biological behavior of stem
cells and the therapeutic mechanisms by which trans-
planted stem cells improve hepatic function and pro-
mote self-rehabilitation.
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